Iradimed Stock Price, News & Analysis (NASDAQ:IRMD)

$13.50 +0.07 (+0.52 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$13.50
Today's Range$13.14 - $13.85
52-Week Range$7.85 - $15.85
Volume2,898 shs
Average Volume21,771 shs
Market Capitalization$141.70 million
P/E Ratio270.00
Dividend YieldN/A
Beta1.45

About Iradimed (NASDAQ:IRMD)

Iradimed logoIRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.

Receive IRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IRMD
CUSIPN/A
Phone407-677-8022

Debt

Debt-to-Equity RatioN/A
Current Ratio8.69%
Quick Ratio7.62%

Price-To-Earnings

Trailing P/E Ratio270
Forward P/E Ratio54.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$23.08 million
Price / Sales6.18
Cash Flow$0.70 per share
Price / Cash19.29
Book Value$2.98 per share
Price / Book4.53

Profitability

Trailing EPS$0.05
Net Income$500,000.00
Net Margins2.17%
Return on Equity3.06%
Return on Assets2.61%

Miscellaneous

Employees80
Outstanding Shares10,560,000

Iradimed (NASDAQ:IRMD) Frequently Asked Questions

What is Iradimed's stock symbol?

Iradimed trades on the NASDAQ under the ticker symbol "IRMD."

How will Iradimed's stock buyback program work?

Iradimed announced that its Board of Directors has authorized a stock repurchase program on Sunday, June 4th 2017, which allows the company to repurchase $8,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its stock is undervalued.

How were Iradimed's earnings last quarter?

Iradimed Corp (NASDAQ:IRMD) issued its quarterly earnings data on Tuesday, February, 6th. The medical equipment provider reported $0.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.02 by $0.04. The medical equipment provider had revenue of $6.70 million for the quarter, compared to the consensus estimate of $6.72 million. Iradimed had a return on equity of 3.06% and a net margin of 2.17%. The business's revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.11 EPS. View Iradimed's Earnings History.

When will Iradimed make its next earnings announcement?

Iradimed is scheduled to release their next quarterly earnings announcement on Friday, April, 27th 2018. View Earnings Estimates for Iradimed.

What guidance has Iradimed issued on next quarter's earnings?

Iradimed issued an update on its FY18 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of $0.33-$0.38 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.35. The company issued revenue guidance of $29.3-$30.0 million, compared to the consensus revenue estimate of $29.70 million.Iradimed also updated its Q1 guidance to $0.06-$0.07 EPS.

Where is Iradimed's stock going? Where will Iradimed's stock price be in 2018?

2 analysts have issued 12-month price objectives for Iradimed's stock. Their forecasts range from $16.00 to $19.00. On average, they expect Iradimed's stock price to reach $17.50 in the next twelve months. View Analyst Ratings for Iradimed.

Who are some of Iradimed's key competitors?

Who are Iradimed's key executives?

Iradimed's management team includes the folowing people:

  • Roger Susi, Chairman of the Board, President, Chief Executive Officer, Founder (Age 62)
  • Chris Scott, Chief Financial Officer, Secretary (Age 44)
  • John McCreery, Chief Operating Officer (Age 62)
  • Brent Johnson, Executive Vice President - Worldwide Sales and Marketing (Age 56)
  • Fran Casey, Vice President - Regulatory and Quality Assurance (Age 60)
  • Steve Nardi, Vice President - Manufacturing (Age 53)
  • Louis Waldman, Controller (Age 59)
  • Jonathan A. Kennedy, Director (Age 46)
  • Anthony Vuoto, Director (Age 64)
  • Monty K. Allen, Independent Director (Age 62)

Who owns Iradimed stock?

Iradimed's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Eversept Partners LLC (0.48%), Renaissance Technologies LLC (0.45%), Boston Partners (0.42%), Spark Investment Management LLC (0.32%), EAM Investors LLC (0.29%) and Unison Advisors LLC (0.28%). Company insiders that own Iradimed stock include Monty K Allen, Roger E Susi, Serge Novovich and Steven M Nardi. View Institutional Ownership Trends for Iradimed.

Who sold Iradimed stock? Who is selling Iradimed stock?

Iradimed's stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC. Company insiders that have sold Iradimed company stock in the last year include Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.

Who bought Iradimed stock? Who is buying Iradimed stock?

Iradimed's stock was acquired by a variety of institutional investors in the last quarter, including Eversept Partners LLC, Boston Partners, Renaissance Technologies LLC, EAM Investors LLC, Unison Advisors LLC, Stone Ridge Asset Management LLC, Cadence Capital Management LLC and Deutsche Bank AG. View Insider Buying and Selling for Iradimed.

How do I buy Iradimed stock?

Shares of Iradimed can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Iradimed's stock price today?

One share of Iradimed stock can currently be purchased for approximately $13.50.

How big of a company is Iradimed?

Iradimed has a market capitalization of $141.70 million and generates $23.08 million in revenue each year. The medical equipment provider earns $500,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. Iradimed employs 80 workers across the globe.

How can I contact Iradimed?

Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]


MarketBeat Community Rating for Iradimed (IRMD)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  107 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  202
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Iradimed (NASDAQ:IRMD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.50$17.50$16.00$12.00
Price Target Upside: 29.63% upside29.63% upside17.22% upside22.45% upside

Iradimed (NASDAQ:IRMD) Consensus Price Target History

Price Target History for Iradimed (NASDAQ:IRMD)

Iradimed (NASDAQ:IRMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/27/2017Credit Suisse GroupInitiated CoverageBuy$19.00LowView Rating Details
10/31/2017Roth CapitalInitiated CoverageBuy -> Buy$16.00N/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Iradimed (NASDAQ:IRMD) Earnings History and Estimates Chart

Earnings by Quarter for Iradimed (NASDAQ:IRMD)

Iradimed (NASDAQ IRMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2018        
2/6/2018Q4 2017$0.02$0.06$6.72 million$6.70 millionViewN/AView Earnings Details
10/30/2017Q3 2017($0.28)$0.07$5.60 million$5.69 millionViewN/AView Earnings Details
7/28/2017Q2 2017($0.01)$0.06$5.41 million$5.50 millionViewN/AView Earnings Details
4/28/2017Q1 2017($0.02)($0.02)$5.26 million$5.16 millionViewN/AView Earnings Details
2/6/2017Q416$0.04$0.11$6.09 million$6.00 millionViewListenView Earnings Details
10/28/2016Q316$0.09$0.14$7.50 million$7.70 millionViewListenView Earnings Details
7/29/2016Q216$0.21$0.24$9.60 million$9.90 millionViewListenView Earnings Details
4/29/2016Q1$0.18$0.21$9.05 million$8.96 millionViewListenView Earnings Details
2/5/2016Q415$0.19$0.22$8.80 million$8.80 millionViewN/AView Earnings Details
10/30/2015Q315$0.16$0.19$7.70 million$8.20 millionViewListenView Earnings Details
7/30/2015Q215$0.12$0.15$7.10 million$7.60 millionViewListenView Earnings Details
4/30/2015Q115$0.10$0.12$6.90 million$7.00 millionViewN/AView Earnings Details
2/5/2015Q4($0.01)$0.02$3.50 million$3.58 millionViewN/AView Earnings Details
10/30/2014Q3$0.01$0.02$3.80 million$3.80 millionViewN/AView Earnings Details
8/12/2014Q214$0.11$2.80 million$4.70 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Iradimed (NASDAQ:IRMD) Earnings Estimates

Current Year EPS Consensus Estimate: $0.25 EPS
Next Year EPS Consensus Estimate: $0.45 EPS

Dividends

Dividend History for Iradimed (NASDAQ:IRMD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Iradimed (NASDAQ IRMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 60.10%
Institutional Ownership Percentage: 15.08%
Insider Trades by Quarter for Iradimed (NASDAQ:IRMD)
Institutional Ownership by Quarter for Iradimed (NASDAQ:IRMD)

Iradimed (NASDAQ IRMD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/4/2017Monty K AllenDirectorSell1,898$13.95$26,477.109,062View SEC Filing  
6/1/2017Steven M NardiVPSell4,634$8.32$38,554.882,194View SEC Filing  
2/9/2017Roger E SusiCEOBuy10,000$8.60$86,000.0015,000View SEC Filing  
11/29/2016Roger E SusiCEOBuy5,000$11.24$56,200.0010,000View SEC Filing  
11/15/2016Roger E SusiCEOBuy5,000$10.46$52,300.005,000View SEC Filing  
8/16/2016Steven M NardiVPSell2,096$17.11$35,862.561,996View SEC Filing  
6/14/2016Monty K. AllenDirectorSell2,275$20.00$45,500.00View SEC Filing  
6/13/2016Monty K AllenDirectorSell2,100$20.44$42,924.004,375View SEC Filing  
2/19/2016Serge NovovichDirectorSell2,910$17.23$50,139.30107,546View SEC Filing  
2/18/2016Steven M NardiVPSell192$17.00$3,264.002,288View SEC Filing  
12/23/2015Roger E SusiCEOSell156,521$23.28$3,643,808.88View SEC Filing  
12/18/2015Roger E SusiCEOSell1,043,479$23.28$24,292,191.12View SEC Filing  
12/16/2015Steven M. NardiVPSell4,438$26.80$118,938.40100View SEC Filing  
12/8/2015Brent JohnsonVPSell22,659$30.92$700,616.28View SEC Filing  
12/7/2015Steven M. NardiVPSell624$31.02$19,356.48600View SEC Filing  
12/4/2015Brent JohnsonVPSell400$31.51$12,604.00View SEC Filing  
12/3/2015Brent JohnsonVPSell26,880$31.52$847,257.60View SEC Filing  
12/1/2015Serge NovovichDirectorSell1,000$31.12$31,120.00100,983View SEC Filing  
11/25/2015James B. HawkinsDirectorSell5,290$30.98$163,884.2083,460View SEC Filing  
8/25/2015Monty K. AllenDirectorSell6,250$24.85$155,312.50View SEC Filing  
12/29/2014Steven M NardiVPBuy2,100$12.58$26,418.00View SEC Filing  
7/21/2014James B HawkinsDirectorBuy80,000$6.25$500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Iradimed (NASDAQ IRMD) News Headlines

Source:
DateHeadline
Iradimed (IRMD) Releases FY18 Earnings GuidanceIradimed (IRMD) Releases FY18 Earnings Guidance
www.americanbankingnews.com - February 6 at 9:42 AM
Iradimed (IRMD) Issues Q1 Earnings GuidanceIradimed (IRMD) Issues Q1 Earnings Guidance
www.americanbankingnews.com - February 6 at 9:24 AM
IRADIMED CORPORATION Announces Fourth Quarter 2017 Financial ResultsIRADIMED CORPORATION Announces Fourth Quarter 2017 Financial Results
finance.yahoo.com - February 6 at 9:02 AM
Iradimed (IRMD) Issues  Earnings Results, Beats Expectations By $0.08 EPSIradimed (IRMD) Issues Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - February 6 at 8:50 AM
Zacks: Analysts Set $14.00 Price Target for Iradimed Corp (IRMD)Zacks: Analysts Set $14.00 Price Target for Iradimed Corp (IRMD)
www.americanbankingnews.com - February 3 at 1:34 PM
Iradimed (IRMD) Downgraded to Hold at Zacks Investment ResearchIradimed (IRMD) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - February 3 at 11:12 AM
Iradimed (IRMD) Scheduled to Post Quarterly Earnings on TuesdayIradimed (IRMD) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - January 30 at 5:26 AM
Iradimed (IRMD) Upgraded by Zacks Investment Research to BuyIradimed (IRMD) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - January 27 at 5:30 PM
Iradimed Corp. (IRMD) FY18 Guides Tops ViewsIradimed Corp. (IRMD) FY18 Guides Tops Views
www.streetinsider.com - January 24 at 9:27 AM
 Iradimed Corp (IRMD) Given $16.00 Consensus Target Price by Analysts Iradimed Corp (IRMD) Given $16.00 Consensus Target Price by Analysts
www.americanbankingnews.com - January 17 at 12:04 PM
Zacks: Analysts Set $16.00 Target Price for Iradimed Corp (IRMD)Zacks: Analysts Set $16.00 Target Price for Iradimed Corp (IRMD)
www.americanbankingnews.com - January 13 at 5:06 PM
Analysts Expect Iradimed Corp (IRMD) to Post $0.06 Earnings Per ShareAnalysts Expect Iradimed Corp (IRMD) to Post $0.06 Earnings Per Share
www.americanbankingnews.com - December 29 at 5:28 AM
IRadimed (IRMD) Hits 52-Week High: What's Driving the Stock?IRadimed (IRMD) Hits 52-Week High: What's Driving the Stock?
finance.yahoo.com - December 27 at 1:27 PM
ETFs with exposure to IRadimed Corp. : December 26, 2017ETFs with exposure to IRadimed Corp. : December 26, 2017
finance.yahoo.com - December 26 at 3:10 PM
IRadimed Corp. :IRMD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017IRadimed Corp. :IRMD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 4:13 PM
 Analysts Expect Iradimed Corp (IRMD) Will Post Earnings of $0.06 Per Share Analysts Expect Iradimed Corp (IRMD) Will Post Earnings of $0.06 Per Share
www.americanbankingnews.com - December 24 at 3:26 PM
Zacks Investment Research Downgrades Iradimed (IRMD) to HoldZacks Investment Research Downgrades Iradimed (IRMD) to Hold
www.americanbankingnews.com - December 21 at 12:12 AM
 Iradimed Corp (IRMD) Receives Average Rating of "Strong Buy" from Analysts Iradimed Corp (IRMD) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - December 18 at 3:28 PM
ETFs with exposure to IRadimed Corp. : December 15, 2017ETFs with exposure to IRadimed Corp. : December 15, 2017
finance.yahoo.com - December 15 at 3:36 PM
Zacks: Analysts Expect iRadimed Corporation (IRMD) Will Post Earnings of $0.06 Per ShareZacks: Analysts Expect iRadimed Corporation (IRMD) Will Post Earnings of $0.06 Per Share
www.americanbankingnews.com - December 6 at 11:28 PM
iRadimed Corporation (IRMD) Director Monty K. Allen Sells 1,898 SharesiRadimed Corporation (IRMD) Director Monty K. Allen Sells 1,898 Shares
www.americanbankingnews.com - December 6 at 9:26 PM
Credit Suisse Group Initiates Coverage on iRadimed Corporation (IRMD)Credit Suisse Group Initiates Coverage on iRadimed Corporation (IRMD)
www.americanbankingnews.com - November 27 at 10:10 AM
 iRadimed Corporation (IRMD) Given Average Rating of "Strong Buy" by Brokerages iRadimed Corporation (IRMD) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 26 at 3:38 PM
Zacks: iRadimed Corporation (IRMD) Receives Consensus Rating of "Strong Buy" from BrokeragesZacks: iRadimed Corporation (IRMD) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - November 20 at 11:50 AM
 Analysts Expect iRadimed Corporation (IRMD) Will Post Earnings of $0.06 Per Share Analysts Expect iRadimed Corporation (IRMD) Will Post Earnings of $0.06 Per Share
www.americanbankingnews.com - November 19 at 3:22 AM
Edited Transcript of IRMD earnings conference call or presentation 30-Oct-17 3:00pm GMTEdited Transcript of IRMD earnings conference call or presentation 30-Oct-17 3:00pm GMT
finance.yahoo.com - October 31 at 11:52 PM
 iRadimed Corporation (IRMD) Receives Average Rating of "Strong Buy" from Analysts iRadimed Corporation (IRMD) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - October 31 at 3:41 PM
IRADIMEDs (IRMD) CEO Roger Susi on Q3 2017 Results - Earnings Call TranscriptIRADIMED's (IRMD) CEO Roger Susi on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - October 30 at 11:08 PM
iRadimed Corporation (IRMD) Updates Q4 Earnings GuidanceiRadimed Corporation (IRMD) Updates Q4 Earnings Guidance
www.americanbankingnews.com - October 30 at 9:38 AM
iRadimed Corporation (IRMD) Announces Quarterly  Earnings Results, Beats Estimates By $0.04 EPSiRadimed Corporation (IRMD) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - October 30 at 8:50 AM
IRadimed Corp.: Price momentum supported by strong fundamentalsIRadimed Corp.: Price momentum supported by strong fundamentals
finance.yahoo.com - October 28 at 7:08 AM
ETFs with exposure to IRadimed Corp. : October 27, 2017ETFs with exposure to IRadimed Corp. : October 27, 2017
finance.yahoo.com - October 28 at 7:08 AM
Iradimed Corp. (IRMD) Granted FDA 510(k) Clearance of MRI Compatible Patient Vital Signs MonitorIradimed Corp. (IRMD) Granted FDA 510(k) Clearance of MRI Compatible Patient Vital Signs Monitor
www.streetinsider.com - October 26 at 2:40 PM
IRADIMED CORPORATION Announces FDA 510(k) Clearance of MRI Compatible Patient Vital Signs MonitorIRADIMED CORPORATION Announces FDA 510(k) Clearance of MRI Compatible Patient Vital Signs Monitor
finance.yahoo.com - October 26 at 2:40 PM
iRadimed Corporation, Expansion Plans Could Lead To 100% Upside, With 40% DownsideiRadimed Corporation, Expansion Plans Could Lead To 100% Upside, With 40% Downside
seekingalpha.com - October 23 at 7:40 PM
iRadimed Corporation (IRMD) Scheduled to Post Quarterly Earnings on MondayiRadimed Corporation (IRMD) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 23 at 9:00 AM
ETFs with exposure to IRadimed Corp. : October 9, 2017ETFs with exposure to IRadimed Corp. : October 9, 2017
finance.yahoo.com - October 9 at 7:59 PM
Apollo Endosurgery (APEN) & iRadimed Corporation (IRMD) Financial ContrastApollo Endosurgery (APEN) & iRadimed Corporation (IRMD) Financial Contrast
www.americanbankingnews.com - October 8 at 12:28 PM
iRadimed Corporation (IRMD) Stock Rating Upgraded by ValuEngineiRadimed Corporation (IRMD) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - October 6 at 10:34 PM
iRadimed Corporation (IRMD) versus Apollo Endosurgery (APEN) Head to Head ReviewiRadimed Corporation (IRMD) versus Apollo Endosurgery (APEN) Head to Head Review
www.americanbankingnews.com - September 29 at 12:30 AM
ETFs with exposure to IRadimed Corp. : September 26, 2017ETFs with exposure to IRadimed Corp. : September 26, 2017
finance.yahoo.com - September 26 at 5:04 PM
IRadimed Corp. :IRMD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017IRadimed Corp. :IRMD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017
finance.yahoo.com - September 25 at 9:29 AM
IRADIMED CORPORATION to Present at Cantor Fitzgerald Global Healthcare ConferenceIRADIMED CORPORATION to Present at Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 18 at 7:26 PM
Entellus Medical (ENTL) and iRadimed Corporation (NASDAQ:IRMD) Critical ComparisonEntellus Medical (ENTL) and iRadimed Corporation (NASDAQ:IRMD) Critical Comparison
www.americanbankingnews.com - August 7 at 4:28 PM
Reviewing Entellus Medical (ENTL) & iRadimed Corporation (NASDAQ:IRMD)Reviewing Entellus Medical (ENTL) & iRadimed Corporation (NASDAQ:IRMD)
www.americanbankingnews.com - August 5 at 12:12 AM
iRadimed Corporation (IRMD) versus Penumbra (PEN) Head to Head AnalysisiRadimed Corporation (IRMD) versus Penumbra (PEN) Head to Head Analysis
www.americanbankingnews.com - August 4 at 10:16 PM
Corporate News Blog - Cesca Therapeutics Announces Issuance of New Cellular Processing PatentCorporate News Blog - Cesca Therapeutics Announces Issuance of New Cellular Processing Patent
finance.yahoo.com - July 31 at 7:23 PM
Analysts Anticipate iRadimed Corporation (NASDAQ:IRMD) to Post $0.00 EPSAnalysts Anticipate iRadimed Corporation (NASDAQ:IRMD) to Post $0.00 EPS
www.americanbankingnews.com - July 31 at 2:34 PM
iRadimed Corporation (NASDAQ:IRMD) Upgraded to Buy by Roth CapitaliRadimed Corporation (NASDAQ:IRMD) Upgraded to Buy by Roth Capital
www.americanbankingnews.com - July 31 at 9:09 AM
IRADIMED CORPORATION Announces Second Quarter 2017 Financial ResultsIRADIMED CORPORATION Announces Second Quarter 2017 Financial Results
finance.yahoo.com - July 28 at 11:34 PM

SEC Filings

Iradimed (NASDAQ:IRMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Iradimed (NASDAQ:IRMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Iradimed (NASDAQ IRMD) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.